Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1952 2
1953 1
1954 2
1957 3
1958 2
1960 1
1962 1
1963 2
1964 3
1965 2
1966 3
1967 5
1968 8
1969 3
1970 7
1971 7
1972 13
1973 9
1974 8
1975 10
1976 9
1977 10
1978 3
1979 6
1980 7
1981 15
1982 6
1983 15
1984 23
1985 21
1986 17
1987 18
1988 19
1989 16
1990 8
1991 34
1992 21
1993 22
1994 17
1995 20
1996 20
1997 17
1998 36
1999 22
2000 12
2001 20
2002 18
2003 30
2004 29
2005 37
2006 18
2007 25
2008 37
2009 32
2010 34
2011 49
2012 48
2013 54
2014 45
2015 51
2016 50
2017 54
2018 50
2019 45
2020 62
2021 51
2022 72
2023 79
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

1,390 results

Results by year

Filters applied: . Clear all
Page 1
Management of Neuroblastoma in Pediatric Patients.
Croteau N, Nuchtern J, LaQuaglia MP. Croteau N, et al. Surg Oncol Clin N Am. 2021 Apr;30(2):291-304. doi: 10.1016/j.soc.2020.11.010. Epub 2021 Feb 10. Surg Oncol Clin N Am. 2021. PMID: 33706901 Review.
Accurate risk determination is essential for optimal surgical therapy. Some tumors like neonatal adrenal neuroblastomas and those in the metastatic category can be observed. Very-low-risk and low-risk neuroblastomas can be treated with surgery alone. Intermediate-ri …
Accurate risk determination is essential for optimal surgical therapy. Some tumors like neonatal adrenal neuroblastomas and th …
Overview and recent advances in the treatment of neuroblastoma.
Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Whittle SB, et al. Expert Rev Anticancer Ther. 2017 Apr;17(4):369-386. doi: 10.1080/14737140.2017.1285230. Epub 2017 Mar 15. Expert Rev Anticancer Ther. 2017. PMID: 28142287 Free article. Review.
Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combin …
Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeuti …
Updates in Diagnosis, Management, and Treatment of Neuroblastoma.
Swift CC, Eklund MJ, Kraveka JM, Alazraki AL. Swift CC, et al. Radiographics. 2018 Mar-Apr;38(2):566-580. doi: 10.1148/rg.2018170132. Radiographics. 2018. PMID: 29528815 Review.
New immunotherapeutic techniques and nuclear medicine-targeted therapies have emerged and are demonstrating promising response rates for patients at high risk. This article reviews updates in the diagnosis, management, and treatment of neuroblastoma that have evolved over …
New immunotherapeutic techniques and nuclear medicine-targeted therapies have emerged and are demonstrating promising response rates …
EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma.
Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, Dangouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Stücklin ASG, Idbaih A, Preusser M, van den Bent M, Weller M, Hau P. Franceschi E, et al. Lancet Oncol. 2019 Dec;20(12):e715-e728. doi: 10.1016/S1470-2045(19)30669-2. Lancet Oncol. 2019. PMID: 31797797 Review.
Our recommendations are a resource for professionals involved in the management of post-pubertal and adult patients with medulloblastoma, for patients and caregivers, and for health-care providers in Europe. The implementation of this guideline requires multidisciplinary s …
Our recommendations are a resource for professionals involved in the management of post-pubertal and adult patients with medulloblastoma, fo …
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Park JR, et al. J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. J Clin Oncol. 2017. PMID: 28471719 Free PMC article. Review.
Primary and metastatic soft tissue sites will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) and iodine-123 ((123)I) -metaiodobenzylguanidine (MIBG) scans or [(18)F]fluorodeoxyglucose-positron emission tomography scans if the tumor is MIBG nonavid. …
Primary and metastatic soft tissue sites will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) and iodine-123 …
MIBG in neuroblastoma diagnosis and treatment.
Olecki E, Grant CN. Olecki E, et al. Semin Pediatr Surg. 2019 Dec;28(6):150859. doi: 10.1016/j.sempedsurg.2019.150859. Epub 2019 Nov 20. Semin Pediatr Surg. 2019. PMID: 31931960 Review.
Neuroblastoma is a heterogenous disease, with solid tumors arising in the adrenal gland or paraspinal regions in young children. ...Long-term survival for the high-risk subset of patients with metastatic disease is <40% despite aggressive multimodal therapy. Deri …
Neuroblastoma is a heterogenous disease, with solid tumors arising in the adrenal gland or paraspinal regions in young children. ...L …
Clinical and pre-clinical utility of genomics in medulloblastoma.
Nör C, Ramaswamy V. Nör C, et al. Expert Rev Neurother. 2018 Aug;18(8):633-647. doi: 10.1080/14737175.2018.1503536. Epub 2018 Jul 26. Expert Rev Neurother. 2018. PMID: 30032687 Review.
Opportunities and challenges in developing new treatment paradigms are summarized and discussed, specifically new therapies for very high-risk metastatic/MYC-amplified Group 3 and TP53-mutant SHH and reductions in therapy for lower risk groups. Expert commentary: Su …
Opportunities and challenges in developing new treatment paradigms are summarized and discussed, specifically new therapies for very …
Cell death-based treatment of neuroblastoma.
Valter K, Zhivotovsky B, Gogvadze V. Valter K, et al. Cell Death Dis. 2018 Jan 25;9(2):113. doi: 10.1038/s41419-017-0060-1. Cell Death Dis. 2018. PMID: 29371588 Free PMC article. Review.
Moreover, NB is a complex disease that has high heterogeneity and is therefore difficult to target for successful therapy. Thus, a better understanding of NB development helps to improve treatment and increase the survival rate. ...In addition, several currently used and i …
Moreover, NB is a complex disease that has high heterogeneity and is therefore difficult to target for successful therapy. Thus, a be …
1,390 results